Figure 1.
Tumor growth for anti-CD25 monoclonal antibody (mAb) treatments. (a) Experimental protocol. C57/BJ6 mice (n=6) were treated, that is, with anti-CD25 mAb, irrelevant IgG mAb or untreated 1 day prior to tumor inoculation and 4 days post tumor inoculation, 5 × 105 B16F10 cells were inoculated subcutaneously to the mice and tumour volume was monitored. (b) Tumor growth curves. Tumor growth from anti-CD25 mAb, irrelevant IgG mAb and untreated is presented as tumor volume measurements from day 0 to day 12. Tumor volume was calculated using the formula V=ab2/6. Data are presented as the means±standard error of the mean. *At days 6, 8, 10 and 12, compared anti-CD25 mAb with untreated and IgG mAb, P<0.05. (c) Survival of tumor-bearing mice. Survival is presented using Kaplan–Meier survival curves. *Compared anti-CD25 mAb with untreated B16F10 and IgG mAb, P<0.02.